MUSC Digestive Disease Research Core Center

MUSC消化疾病研究核心中心

• 批准号: 10608960
• 负责人: DON C. ROCKEY
• 金额: $ 108.76万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-04-15 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10608960
• 关键词: Acceleration; Area; Award; Basic Science; Biology; Biomedical Research; Cell model; Cells; Clinical; Clinical Research; Clinical Sciences; Collaborations; Colon; Complement; Core Facility; Curiosities; Dedications; Development; Digestive System Disorders; Disease; Ensure; Esophagitis; Esophagus; Evaluation; Fibrosis; Fostering; Foundations; Functional disorder; Funding; Gastrointestinal Diseases; Gastrointestinal tract structure; Goals; Health; Healthcare; Hepatocyte; Image; Imaging Techniques; Inflammation; Inflammatory Bowel Diseases; Injury; Institution; Investigation; Investments; Leadership; Liver; Liver diseases; Malignant Neoplasms; Medical; Mentorship; Mission; Modeling; National Institute of Diabetes and Digestive and Kidney Diseases; Organ; Pancreas; Participant; Pathogenesis; Patient-Focused Outcomes; Patients; Performance; Proteomics; Research; Research Infrastructure; Research Personnel; Resources; Scholarship; Science; Scientific Inquiry; Small Intestines; South Carolina; Stomach; Structure; Technology; Tissues; Translating; Translational Research; Universities; Vision; Work; base; career development; cell injury; chronic pancreatitis; design; driving force; flexibility; gastrointestinal; human disease; human model; imaging capabilities; improved; innovation; instrumentation; liver injury; mass spectrometric imaging; member; novel; novel therapeutics; organ injury; process improvement; programs; research study; success; tissue culture

Center Overview - Abstract The vision for the Medical University of South Carolina (MUSC) Digestive Disease Research Core Center (DDRCC) is to create a culture of curiosity, scholarship, and investigation around our central theme. Our theme is informed by the pathogenesis of disease in the gastrointestinal tract, from cellular injury, inflammation, fibrosis, and ultimately end organ dysfunction and disease. Our specific emphasis on human disease is part of our rationale for the extension of the continuum of our theme - from injury to disease. Further, we expect the work by Center members to lead to new treatments for patients with gastrointestinal disease. Our specific aims are integrated with the specific goal to serve our Research Base/Full Members and our mission; specific aims are as follows: (1) First, we will foster collaboration among digestive and liver disease researchers. We will leverage collaborations among MUSC investigators to further augment our research capacity while ensuring the success of a critical mass of outstanding researchers in digestive and liver diseases. This will be supported through multiple synergistic efforts as described in the Administrative Core including DDRCC leadership and Enrichment and Pilot and Feasibility Programs. (2) We will develop sustainable scientific core resources that will specifically support digestive and liver disease studies while leveraging institutional investments. The DDRCC scientific cores include: a) Analytical Cell Models Core, which will deliver high quality, pure primary liver cells and produce state-of-the-art tissue culture models; b) Advanced Imaging Core with advanced cell- and tissue-based imaging techniques and instrumentation; and c) Proteomics Core with innovative mass spectrometry imaging capabilities. These cores are complemented by a committed Clinical Component which provides support for the design, implementation and analysis of research studies to improve clinical outcomes for patients with digestive diseases. Finally, we will (3) Promote the long- term success and sustainability of the DDRCC through dedicated mentorship of New Investigators, a rigorous Center evaluation and process improvement strategy, mission alignment with other centers at MUSC, and specific long-term institutional commitments to the Center. The MUSC DDRCC is made up of 29 Full Members focused specifically on our theme, and who constitute our Research Base of $10.8M. We also have 31 Associate Members who are active participants in the Center. The DDRCC has enormous potential to answer important questions, open new areas for further inquiry, and result in potential new therapeutic discoveries that will be translated to new treatments for patients with digestive and liver disease.

中心概述 - 摘要 南卡罗来纳州医科大学（MUSC）消化疾病研究核心中心的愿景 （DDRCC）是建立围绕我们的中心主题的好奇心，学术和调查的文化​​。我们的主题 由胃肠道的疾病发病机理，来自细胞损伤，炎症，纤维化， 并最终结束器官功能障碍和疾病。我们对人类疾病的具体强调是我们的一部分 从伤害到疾病的连续体扩展我们的主题的基本原理。此外，我们希望这项工作 中心成员为胃肠道疾病患者提供新的治疗方法。 我们的具体目标与为我们的研究基础/完整成员和使命服务的具体目标融合在一起； 具体目的如下：（1）首先，我们将促进消化和肝病之间的协作 研究人员。我们将利用MUSC调查人员之间的合作来进一步增强我们的研究 能力同时确保了批判性杰出研究人员在消化和肝病中的成功。 这将通过行政核心中所述的多种协同工作来支持这一点 DDRCC领导力和丰富以及飞行员和可行性计划。 （2）我们将发展可持续 科学核心资源将专门支持消化和肝病研究 利用机构投资。 DDRCC科学核心包括：a）分析细胞模型核心， 它将提供高质量的纯原代肝细胞并产生最先进的组织培养模型； b） 具有晚期细胞和基于组织的成像技术和仪器的高级成像核；和c） 具有创新质谱成像功能的蛋白质组学核心。这些核心与 致力于研究，实施和分析研究的临床组件 改善消化系统疾病患者的临床结果的研究。最后，我们将（3）促进长期 DDRCC的“成功和可持续性”通过新调查人员的专门指导，这是一个严格的 中心评估和过程改进策略，与MUSC其他中心的任务一致以及 对中心的特定长期制度承诺。 MUSC DDRCC由29个专门针对我们主题的正式成员组成，谁构成了我们 研究基础为1,080万美元。我们还有31名积极参与者的同学成员。这 DDRCC具有回答重要问题的巨大潜力，开放新领域以进行进一步询问，并导致 潜在的新治疗发现，该发现将转化为消化和消化患者的新疗法 肝病。

项目成果

An Unsuccessful Randomized Trial of Percutaneous vs Endoscopic Drainage of Suspected Malignant Hilar Obstruction.

• DOI: 10.1016/j.cgh.2020.05.035
• 发表时间: 2021-06
• 期刊: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
• 作者: Elmunzer BJ;Smith ZL;Tarnasky P;Wang AY;Yachimski P;Banovac F;Buscaglia JM;Buxbaum J;Chak A;Chong B;Coté GA;Draganov PV;Dua K;Durkalski V;Geller BS;Jamil LH;Keswani RN;Khashab MA;Law R;Lo SK;McCarthy S;Selby JB;Singh VK;Taylor JR;Willingham FF;Spitzer RL;Foster LD;INTERCPT study group and the United States Cooperative for Outcomes Research in Endoscopy (USCORE)
• 通讯作者: INTERCPT study group and the United States Cooperative for Outcomes Research in Endoscopy (USCORE)

A phylogenetic approach for weighting genetic sequences.

• DOI: 10.1186/s12859-021-04183-8
• 发表时间: 2021-05-28
• 期刊: BMC bioinformatics
• 影响因子: 3
• 作者: De Maio N;Alekseyenko AV;Coleman-Smith WJ;Pardi F;Suchard MA;Tamuri AU;Truszkowski J;Goldman N
• 通讯作者: Goldman N

The impact of pretransplant opioid exposure on healthcare utilization and costs in kidney transplant.

移植前阿片类药物暴露对医疗保健利用率和肾移植成本的影响。

• DOI: 10.1002/phar.2479
• 发表时间: 2021
• 期刊: Pharmacotherapy
• 影响因子: 4.1
• 作者: Wise,Bailey;Wilson,LytaniZ;Taber,DavidJ;Pilch,NicoleA;Rohan,Vinayak;Fleming,JamesN
• 通讯作者: Fleming,JamesN

Increased rebleeding and mortality in patients with gastrointestinal bleeding treated with anticoagulant drugs compared to antiplatelet drugs.

与抗血小板药物相比，接受抗凝药物治疗的消化道出血患者的再出血和死亡率增加。

• DOI: 10.1097/meg.0000000000002148
• 发表时间: 2021
• 期刊: European journal of gastroenterology & hepatology
• 影响因子: 2.1
• 作者: Hosni,Mohammad;Rahal,Mahmoud;Tamim,Hani;Daniel,Fady;AlHashash,Jana;Sharara,AlaI;Soweid,Assaad;Shaib,YasserH;Mourad,FadiH;Wehbeh,AntoniosN;Rockey,DonC;Barada,Kassem
• 通讯作者: Barada,Kassem

A cross-sectional study of United States family medicine residency programme director burnout: implications for mitigation efforts and future research.

美国家庭医学住院医师项目主任倦怠的横断面研究：对缓解努力和未来研究的影响。

• DOI: 10.1093/fampra/cmaa075
• 发表时间: 2020
• 期刊: Family practice
• 影响因子: 2.2
• 作者: Psenka,TamathaM;Freedy,JohnR;Mims,LisaD;DeCastro,AlecO;Berini,CaroleR;Diaz,VanessaA;Jarrett,JennieB;Steyer,TerrenceE
• 通讯作者: Steyer,TerrenceE